TerminatedPhase 1

A Study of LY3463251 in Healthy Participants

Stopped: Trial was terminated due to an insufficient benefit/tolerability ratio

United States118 participantsStarted 2018-12-06

Plain-language summary

The purpose of this study is to evaluate the safety and tolerability (side effects) of single (Part A) and multiple (Part B) doses of the study drug when it is administered subcutaneously (under the skin) into the abdomen. This is a two-part study. Participants will enroll in only one part. For each participant, Part A will last about 10 weeks and Part B will last about 23 weeks, including screening.

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Healthy males and females Exclusion Criteria: * Diagnosed with Type 1 or Type 2 diabetes * Women who are of childbearing potential or who are breastfeeding * Donated blood of more than 500 millilitres (mL) within the previous 3 months of study screening * Have used any tobacco product within 3 months of Day -1, or are unwilling to refrain from the use of tobacco during the study

What they're measuring

Number of Participants With One or More Adverse Event(s) (AEs), All Causalities

Timeframe: Baseline through follow up in Part A (up to Day 42); Baseline through follow up in Part B (up to Day 123)

Trial details

NCT IDNCT03764774

SponsorEli Lilly and Company

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2020-12-07

Results submitted2025-08-21

View on ClinicalTrials.gov More Healthy trials